CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-01 | Ho Robert Chief Financial Officer | Grant or award · Restricted Stock Units | +70,000 | 70,000 | ||
| 2021-08-03 | Ho Robert Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2021-03-17 | Ho Robert Chief Financial Officer | Sale | −6,497 | $11.01 | $72K | 21,503 |
| 2021-03-16 | Ho Robert Chief Financial Officer | Option exercise | +25,000 | 28,000 | ||
| 2021-03-16 | Ho Robert Chief Financial Officer | Option exercise · Restricted Stock Units | +25,000 | 50,000 | ||
| 2020-08-10 | Ho Robert Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2020-03-16 | Ho Robert Chief Financial Officer | Grant or award · Restricted Stock Units | +75,000 | 75,000 | ||
| 2020-03-16 | Ho Robert Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 |
Page 1 of 1 · 8 trades